New drug combo shows promise against tough esophageal cancer
NCT ID NCT07263919
First seen Jan 11, 2026 · Last updated May 10, 2026 · Updated 16 times
Summary
This study tests whether adding the drug cadonilimab to standard chemotherapy before and after surgery helps people with a certain type of esophageal cancer. About 90 adults with resectable, locally advanced esophageal squamous cell carcinoma will take part. The goal is to see if the combination leads to more complete tumor removal and better long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE LOCALLY ADVANCED THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Air Force Medical University
RECRUITINGXi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.